


NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over ID6377

Provisional Stakeholder List


Provisional stakeholder list for the evaluation of ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over ID6377 Issue date: March 2024



Consultees Commentators (no right to submit or appeal) Relevant research groups British Society of Blood and Marrow Cochrane Haematological Malignancies Transplantation and Cellular Therapy British Paediatric Allergy, Immunity Group and Infection Group (BPAIIG) Cochrane UK **British Transplantation Society** Genomics England Cancer Research UK Leukaemia Busters Neonatal and Paediatric Pharmacists MRC Clinical Trials Unit Group National Institute for Health Research NHS Blood and Transplant Oxford Biomedical Research Centre Royal College of General Practitioners Royal College of Nursing Associated Public Health groups Public Health Wales Royal College of Paediatrics and Child Health **UK Health Security Agency** Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine **UK Clinical Pharmacy Association** UK Forum on Haemoglobin Disorders **UK Primary Immunodeficiency** Network Others Department of Health and Social Care • Christie Haematology and Transplant Unit (Manchester) King's College London - Haematooncology department **NHS** England St James University Hospital Bone Marrow Transplant Department (Leeds Teaching Hospitals Trust) University College London Hospitals

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

HSCT Service



Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.